Sensulin

2 known investors

Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.

BiotechMedical Devices